XOMA XOMA Corporation: רווח נקי למניה בארבעת הרבעונים האחרונים

XOMA Royalty acts as a financial ally for biotech startups by acquiring rights to future cash flows. The business has completely abandoned its own laboratories, focusing instead on monitoring the achievements of its partners. Broad exposure across various therapeutic areas mitigates the risks of individual drug failures. This price chart illustrating value trends shows that the current EPS is 249.30, confirming the effectiveness of the license aggregator model.
XOMA Royalty Corporation - פילוחים אנליטיים ומדדי מפתח (XOMA)

The stability of XOMA Royalty is driven by the expansion of its biotechnology royalty portfolio and a low risk profile. This chart reflects the dynamics of net earnings per share over a rolling twelve-month period, capturing the real rate of capital growth. A positive annual EPS growth rate over the last 12 months confirms the effectiveness of the company's drug monetization. The indicator's steady upward trend serves as a basis for revising the business's fair value upward.